Targets › HDAC (class I/II)
26 programs from 24 companies in 105 trials: 51 Phase 1, 42 Phase 2, 11 Phase 3, 1 Phase 4; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: the race on HDAC (class I/II), likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | panobinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 4 | Primary Myelofibrosis; Sickle Cell Disease | Apr 2032 |
| Italfarmaco | Givinostat Hydrochloride Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Polycythemia Vera; Duchenne Muscular Dystrophy; Chronic Myeloproliferative Neoplasms | Dec 2026 |
| Xynomic Pharmaceuticals | Abexinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Renal Cell Carcinoma; Lymphoma, Follicular; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma … | Dec 2026 |
| Chengdu Zenitar Biomedical Technology | Purinostat Mesylate for Injection Class Ia and IIb HDAC selective inhibitor | HDAC (class I/II) | Phase 3 | Recurrent and Refractory Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma,DLBCL; Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Relapsed or Refractory Multiple Myeloma (RRMM) … | Dec 2026 |
| National Cancer Institute (NCI) | Entinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Anatomic Stage III Breast Cancer AJCC v8; Clear Cell Renal Cell Carcinoma; Advanced Malignant Solid Neoplasm | Feb 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Chidemide Histone deacetylase (HDAC) inhibitor | HDAC (class I/II) | Phase 3 | Newly Diagnosed Peripheral T-cell Lymphoma | Feb 2028 |
| Chipscreen Biosciences | Tucidinostat HDAC inhibitor | HDAC (class I/II) | Phase 3 | Colorectal Cancer; Lymphoma, T-Cell, Peripheral | May 2028 |
| Acrotech Biopharma | Belinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Peripheral T Cell Lymphoma; Locally Advanced Unresectable Primary Central Chondrosarcoma; Carcinoma, Neuroendocrine; Metastatic Uveal Melanoma … | Jul 2030 |
| Tianjin Medical University Cancer Institute and Hospital | Chidamide Histone deacetylase (HDAC) inhibitor | HDAC, HDAC (class I/II) | Phase 2 | Diffuse Large B-Cell Lymphoma-Recurrent; Metastatic Pancreatic Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Neuroblastoma (NB) | Dec 2026 |
| The First Affiliated Hospital with Nanjing Medical University | Chidamide Selective histone deacetylase (HDAC) inhibitor | HDAC (class I/II) | Phase 2 | Double Expressor DLBCL; Chidamide | Mar 2027 |
| Great Novel Therapeutics Biotech & Medicals | Chidamide Histone deacetylase (HDAC) inhibitor | HDAC (class I/II) | Phase 2 | Relapsed or Refractory Peripheral T-cell Lymphoma; Metastatic Microsatellite-stable Colorectal Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Colorectal Cancer Metastatic … | Jun 2027 |
| Stephen Chan Lam | Zabadinostat (CXD101) Histone deacetylase (HDAC) inhibitor | HDAC (class I/II) | Phase 2 | HCC | Dec 2027 |
| University of Virginia | Romidepsin Histone deacetylase inhibitor | HDAC (class I/II) | Phase 2 | PTCL; Lymphoma, T-Cell | Jun 2028 |
| Centre Leon Berard | Chemotherapy + Valproate Multi-agent chemotherapy (vincristine, carboplatin, methotrexate, cyclophosphamide, cispla | HDAC (class I/II) | Phase 2 | Childhood Ependymoma | Jun 2028 |
| University of Miami | Quisinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 2 | Uveal Melanoma | May 2030 |
| Shanghai Jiao Tong University School of Medicine | Chidamide HDAC3 inhibitor | HDAC (class I/II) | Phase 2 | APL | – |
| Jonsson Comprehensive Cancer Center | Mocetinostat Histone deacetylase 1 inhibitor; Histone deacetylase 2 inhibitor; Histone deacetylase 3 inhibitor | HDAC (class I/II) | Phase 1 | Rhabdomyosarcoma | Dec 2026 |
| Unravel Biosciences | Vorinostat Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor | HDAC (class I/II) | Phase 1 | Rett Syndrome; Pitt Hopkins Syndrome; Castration-Resistant Prostate Carcinoma; Metastatic Uveal Melanoma … | Dec 2026 |
| Dana-Farber Cancer Institute | Ricolinostat (ACY-1215) Histone deacetylase 6 inhibitor | HDAC (class I/II) | Phase 1 | Recurrent Chronic Lymphoid Leukemia | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | Mocetinostat Histone deacetylase 1 inhibitor; Histone deacetylase 2 inhibitor; Histone deacetylase 3 inhibitor | HDAC (class I/II) | Phase 1 | Lung Cancer | Jul 2027 |
| Daiichi Sankyo | Valemetostat (DS-3201b) Histone deacetylase inhibitor | HDAC (class I/II) | Phase 1 | Metastatic Castration-resistant Prostate Cancer; Aggressive Variant Prostate Carcinoma; Extensive-stage Small-cell Lung Cancer; Lymphoma … | Jan 2028 |
| Novelwise Pharmaceutical | NBM-BMX HDAC8 inhibitor | HDAC (class I/II) | Phase 1 | Metastatic Uveal Melanoma; Malignant Neoplasm; Malignant Neoplasm of Brain | Mar 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Romidepsin Histone deacetylase inhibitor | HDAC (class I/II) | Phase 1 | Bladder Cancer | Apr 2028 |
| Jubilant Therapeutics | JBI-802 CoREST inhibitor dual targeting LSD1 and HDAC6 | LSD1, HDAC (class I/II) | Phase 1 | Essential Thrombocythemia (ET); Lung Cancer (NSCLC) | Jun 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Domatinostat HDAC inhibitor | HDAC (class I/II) | Phase 1 | Sarcoma | Aug 2031 |
| Priyanka Sharma | Romidepsin Histone deacetylase inhibitor | HDAC (class I/II) | Phase 1 | Triple-Negative Breast Cancer | – |
Metastatic Uveal Melanoma (3) Diffuse Large B-Cell Lymphoma (DLBCL) (3) Peripheral T Cell Lymphoma (3) Duchenne Muscular Dystrophy (3) Breast Cancer (2) Lung Cancer (2) Acute Myeloid Leukemia (2) Diffuse Large B-Cell Lymphoma (2) Leukemia, Myeloid, Acute (2) Anatomic Stage III Breast Cancer AJCC v8 (2) HCC (2) Renal Cell Carcinoma (1)
small molecule (16), mixed (8), antibody (2)
H. Lee Moffitt Cancer Center and Research Institute (2) The First Affiliated Hospital with Nanjing Medical University (2) Xynomic Pharmaceuticals (1) Shanghai Jiao Tong University School of Medicine (1) Jubilant Therapeutics (1) Unravel Biosciences (1) Great Novel Therapeutics Biotech & Medicals (1) Jonsson Comprehensive Cancer Center (1) Italfarmaco (1) Daiichi Sankyo (1) University of Virginia (1) Chengdu Zenitar Biomedical Technology (1) Tianjin Medical University Cancer Institute and Hospital (1) University of Miami (1) Acrotech Biopharma (1) Novelwise Pharmaceutical (1) National Cancer Institute (NCI) (1) Chipscreen Biosciences (1) Stephen Chan Lam (1) Dana-Farber Cancer Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.